Description

Ceruletide is a decapeptide and a potent cholecystokinin receptor agonist. Ceruletide is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts[1].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–COVID-19-immunoregulation–C58H73N13O21S2—-[1]Steinle AU, et al. NF-kappaB/Rel activation in cerulein pancreatitis. Gastroenterology. 1999 Feb;116(2):420-30.|[2]Vincent ME, et al. Pharmacology, clinical uses, and adverse effects of ceruletide, a cholecystokinetic agent. Pharmacotherapy. 1982 Jul-Aug;2(4):223-34.|[3]Bridger N, et al. Comparison of postprandial and ceruletide serum bile acid stimulation in dogs. J Vet Intern Med. 2008 Jul-Aug;22(4):873-8.|[4]Zarrindast MR, et al. Effects of cholecystokinin receptor agonist and antagonists on morphin dependence in mice. Pharmacol Toxicol. 1995 Dec;77(6):360-4.|[5]Ke-You Zhang, et al. Chemically Induced Models of Pancreatitis. 2022. Pancreapedia: Exocrine Pancreas Knowledge Base, DOI: 10.3998/panc.2022.01|[6]Wu Z, et al. Dopamine D2 Receptor Signaling Attenuates Acinar Cell Necroptosis in Acute Pancreatitis through the Cathepsin B/TFAM/ROS Pathway. Oxid Med Cell Longev. 2022 Jul 26;2022:4499219. |[7]Kong L, et al. Sitagliptin activates the p62-Keap1-Nrf2 signalling pathway to alleviate oxidative stress and excessive autophagy in severe acute pancreatitis-related acute lung injury. Cell Death Dis. 2021 Oct 11;12(10):928. |[8]Malla SR, et al. Early trypsin activation develops independently of autophagy in caerulein-induced pancreatitis in mice. Cell Mol Life Sci. 2020 May;77(9):1811-1825.|[9]Lin Y, et al. Neddylation pathway alleviates chronic pancreatitis by reducing HIF1α-CCL5-dependent macrophage infiltration. Cell Death Dis. 2021 Mar 15;12(3):273. –17650-98-5–1352.41–99.96–O=C(N[C@@H](CCSC)C(N[C@@H](CC(O)=O)C(N[C@H](C(N)=O)CC1=CC=CC=C1)=O)=O)[C@@H](NC(CNC([C@@]([C@H](O)C)([H])NC([C@@H](NC([C@H](CC(O)=O)NC([C@H](CCC(N)=O)NC([C@H](CC2)NC2=O)=O)=O)=O)CC3=CC=C(OS(=O)(O)=O)C=C3)=O)=O)=O)CC4=CNC5=C4C=CC=C5–Metabolic Disease; Cardiovascular Disease; Endocrinology–DMF : 16.67 mg/mL (ultrasonic)|DMSO : 100 mg/mL (ultrasonic)|H2O : 2.5 mg/mL (ultrasonic)–Cholecystokinin Receptor—-GPCR/G Protein;Neuronal Signaling–Peptides